These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 12060552

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Recurrence and prognostic factors after treatment with antithyroid agents in Graves-Basedow disease. Multicenter study in Northern Spain].
    Menéndez Torre E, Anda Apiñaniz E, Barbería Layana JJ, Valdés Gallego N, Rabal Artal A, Díaz-Cadórniga F, Santamaría Sandi J, Vázquez García JA.
    Rev Clin Esp; 2000 Feb; 200(2):69-73. PubMed ID: 10776037
    [Abstract] [Full Text] [Related]

  • 4. [Clinical evolution of a cohort of patients with Graves-Basedow disease treated with metimazole].
    De Luis DA, Arconada A, Aller R, Cuéllar LA, Terroba MC, Martín Gil J.
    Med Clin (Barc); 2002 Jun 01; 118(20):777-8. PubMed ID: 12049693
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
    Liu X, Shi B, Li H.
    Ann Endocrinol (Paris); 2015 Dec 01; 76(6):679-83. PubMed ID: 26514949
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Does antithyroidal drug dose influence relapse of treated Graves-Basedow disease?].
    Jover Díaz F, Domínguez Escribano JR.
    An Med Interna; 2004 May 01; 21(5):259-60. PubMed ID: 15176936
    [No Abstract] [Full Text] [Related]

  • 10. Outcome of Graves' disease after antithyroid drug treatment in Taiwan.
    Wang PW, Liu RT, Tung SC, Chien WY, Lu YC, Chen CH, Kuo MC, Hsieh JR, Wang ST.
    J Formos Med Assoc; 1998 Sep 01; 97(9):619-25. PubMed ID: 9795530
    [Abstract] [Full Text] [Related]

  • 11. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
    Kim YA, Cho SW, Choi HS, Moon S, Moon JH, Kim KW, Park DJ, Yi KH, Park YJ, Cho BY.
    Thyroid; 2017 Apr 01; 27(4):491-496. PubMed ID: 28001121
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Soluble intercellular adhesion molecule-1 and Graves' disease.
    Escobar-Morreale HF, Serrano J, Sancho JM, Varela C.
    Thyroid; 1997 Oct 01; 7(5):801-3. PubMed ID: 9349588
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE, Basedow Study Group.
    Thyroid; 2005 Sep 01; 15(9):1047-54. PubMed ID: 16187913
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Clinical significance of elevated serum triiodothyronine to thyroxine ratios in patients with Graves' disease treated with antithyroid drugs].
    Takamatsu J.
    Nihon Naibunpi Gakkai Zasshi; 1983 Mar 20; 59(3):295-303. PubMed ID: 6190686
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.